Combination chemotherapy with cyclophosphamide, vincristine, VP-16, adriamycin and prednisolone was given in 9 cases of mycosis fungoides in the tumor stage; 3 of these patients received COP, one received CHOP, and 5 CAVOP. Complete remission was obtained in one case and partial remission in 5, the response rate thus being 6/9. It was impossible, however, to maintain remission. The treatment was reduced or withdrawn owing to toxic effects in 4 cases. These forms of combination chemotherapy are beneficial in non-Hodgkin lymphomas but do not seem to be of value in the tumour stage of mycosis fungoides.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pediatric Mycosis Fungoides Mimicking Benign Dermatoses: A Report of a Rare Case.
Am J Case Rep
January 2025
Department of Pathology, Hospital Selayang, Batu Caves, Selangor, Malaysia.
BACKGROUND Primary cutaneous lymphomas (PCL) are a multifaceted spectrum of cutaneous T cell lymphoma (CTCL) and cutaneous B cell lymphomas (CBCL). Mycosis fungoides (MF) is a rare subset of CTCL that primarily affects adults, and its occurrence in children is exceedingly rare. Most pediatric MF manifests as hypopigmented patches resembling other benign dermatoses, causing diagnostic challenges.
View Article and Find Full Text PDFMycosis fungoides and Sézary syndrome - Simplifying the approach for dermatologists. Part 1: Etiopathogenesis, clinical features and evaluation.
Indian J Dermatol Venereol Leprol
January 2025
Department of Nuclear Medicine, Army Hospital Research and Referral, New Delhi, India.
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of extranodal non-Hodgkin's lymphomas characterised by a cutaneous infiltration of malignant monoclonal T lymphocytes. While this broad spectrum of disease with its varied etiopathogenesis, clinical features and management options are well characterised, an approach from a dermatologist's perspective is lacking in the literature. We strive to elucidate the approach from a clinician's point of view, especially in respect of clinical examination, investigations, staging and management options that are available in the realm of the dermatologists.
View Article and Find Full Text PDFPityriasis Lichenoides Chronica-Like Mycosis Fungoides: A Diagnostic Dilemma.
Skinmed
January 2025
Department of Skin & VD, Civil Hospital, BJ Medical College, Ahmedabad, Gujarat, India.
Mycosis fungoides (MF) is a neoplasm of the immune system. It is a cutaneous lymphoma originating in the peripheral epidermotropic T-cells, specifically the memory T-cells (CD45RO+). The etiology of MF is indefinite, but various factors, such as genetic and epigenetic abnormalities, environmental and occupational exposure to chemicals, infections, and cytokines (interleukin [IL]-2, IL-4, etc.
View Article and Find Full Text PDFThe Risk of Developing Keratinocyte Malignancies in Patients with Cutaneous T-cell Lymphoma.
J Invest Dermatol
December 2024
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA. Electronic address:
Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides.
An Bras Dermatol
December 2024
Dermatology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Seyrantepe, İstanbul, Turkey.
Background: There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).
Objectives: It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.
Methods: A total of 40 patients with stage IA-IB MF were enrolled in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!